An analysis of drugs known to exhibit potency in MSI-High Mut p53 cell lines revealed that most drugs inhibit kinases belonging to pathways known to be aberrant in MSI cancer cells (e.g., MAPK, ERK, PI3K, TGFB, WNT, and mTOR signaling pathways (Figure 4)), while RIOK1-specific inhibition is novel. This evidence concerns the gene MTOR and cancer.